| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| F M Leweke, D Piomelli, F Pahlisch, D Muhl, C W Gerth, C Hoyer, J Klosterkötter, M Hellmich, D Koeth. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational psychiatry. vol 2. 2013-03-04. PMID:22832859. |
in our translational approach, we performed a double-blind, randomized clinical trial of cannabidiol vs amisulpride, a potent antipsychotic, in acute schizophrenia to evaluate the clinical relevance of our initial findings. |
2013-03-04 |
2023-08-12 |
Not clear |
| Hema Tharoor, R Padmavat. Tardive dyskinesia with low dose amisulpride. Indian journal of psychiatry. vol 55. issue 1. 2013-02-27. PMID:23440033. |
based on experimental data, amisulpride is the drug of choice for dopaminergic transmission disorders, both in depression and in schizophrenia. |
2013-02-27 |
2023-08-12 |
Not clear |
| Richard J Stevenso. Amisulpride overdose: suggested management of prolonged QTc. Emergency medicine journal : EMJ. vol 27. issue 7. 2012-10-10. PMID:20584965. |
amisulpride is used for the treatment of schizophrenia and part of its safety profile is that is has no effect on the qt interval in therapeutic doses. |
2012-10-10 |
2023-08-12 |
Not clear |
| Hyun-Ghang Jeong, Moon-Soo Lee, Hwa-Young Lee, Young-Hoon Ko, Changsu Han, Sook-Haeng Jo. Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study. International clinical psychopharmacology. vol 27. issue 4. 2012-09-27. PMID:22407277. |
in this prospective, open-label study, the participants were 10 male schizophrenia patients treated with atypical antipsychotics, risperidone, amisulpride, and olanzapine. |
2012-09-27 |
2023-08-12 |
human |
| Hyun-Ghang Jeong, Moon-Soo Lee, Hwa-Young Lee, Young-Hoon Ko, Changsu Han, Sook-Haeng Jo. Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study. International clinical psychopharmacology. vol 27. issue 4. 2012-09-27. PMID:22407277. |
our results suggest that sexual dysfunction in schizophrenia patients seems to improve after switching to aripiprazole from other atypical antipsychotics (risperiodone, amisulpride, or olanzapine). |
2012-09-27 |
2023-08-12 |
human |
| Yoshihiro Tadori, Tetsuro Kikuch. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. vol 32. issue 1. 2012-09-13. PMID:22568121. |
antipsychotics (risperidone, olanzapine, amisulpride, sulpiride and perphenazine) which displayed antidepressive effects in schizophrenia patients behaved as preferential antagonists in cells expressing d2 receptors compared to cells expressing d3 receptors. |
2012-09-13 |
2023-08-12 |
human |
| Yong Min Ahn, Kyu Young Lee, Chul-Eung Kim, Dae-Yeob Kang, Jeong-Ho Seok, Young Min Shin, In-Won Chung, Tae-Youn Jun, Jae Seung Chang, Yong Sik Ki. The acute and long-term effectiveness of amisulpride in patients with schizophrenia: results of a 12-month open-label prospective follow-up study. Human psychopharmacology. vol 26. issue 8. 2012-09-06. PMID:22139601. |
the acute and long-term effectiveness of amisulpride in patients with schizophrenia: results of a 12-month open-label prospective follow-up study. |
2012-09-06 |
2023-08-12 |
Not clear |
| Yong Min Ahn, Kyu Young Lee, Chul-Eung Kim, Dae-Yeob Kang, Jeong-Ho Seok, Young Min Shin, In-Won Chung, Tae-Youn Jun, Jae Seung Chang, Yong Sik Ki. The acute and long-term effectiveness of amisulpride in patients with schizophrenia: results of a 12-month open-label prospective follow-up study. Human psychopharmacology. vol 26. issue 8. 2012-09-06. PMID:22139601. |
to compare the effectiveness of amisulpride in acute (up to 8 weeks) and maintenance (week 8 to 12 months) phases of a 12-month course of treatment in a heterogeneous group of patients with schizophrenia. |
2012-09-06 |
2023-08-12 |
Not clear |
| E Y Kim, S H Kim, N Y Lee, D C Jung, Y S Kim, Y M Ah. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride. Pharmacopsychiatry. vol 45. issue 2. 2012-07-16. PMID:22411694. |
relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride. |
2012-07-16 |
2023-08-12 |
Not clear |
| E Y Kim, S H Kim, N Y Lee, D C Jung, Y S Kim, Y M Ah. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride. Pharmacopsychiatry. vol 45. issue 2. 2012-07-16. PMID:22411694. |
we have investigated the categorical prevalence of hyperprolactinemia and examined the relationship between prolactin levels and subjective endocrine-related adverse effects in schizophrenia patients treated with amisulpride during a 1-year period. |
2012-07-16 |
2023-08-12 |
Not clear |
| Hsiu-Wen Chiu, Yu-Chi Ku, Tien-Chun Li, Hsin-Te Huan. Amisulpride augmentation of clozapine in refractory schizophrenia. The Journal of neuropsychiatry and clinical neurosciences. vol 23. issue 3. 2012-01-25. PMID:21948906. |
amisulpride augmentation of clozapine in refractory schizophrenia. |
2012-01-25 |
2023-08-12 |
Not clear |
| Javier Quintero, Eduardo Barbudo, Juan D Molina, Carlos Mur, Antonio Ceverino, Eloy Garcia-Resa, Javier Correas Lauffe. The effectiveness of the combination therapy of amisulpride and quetiapine for managing treatment-resistant schizophrenia: a naturalistic study. Journal of clinical psychopharmacology. vol 31. issue 2. 2011-12-21. PMID:21364334. |
the effectiveness of the combination therapy of amisulpride and quetiapine for managing treatment-resistant schizophrenia: a naturalistic study. |
2011-12-21 |
2023-08-12 |
Not clear |
| Ana Paula Werneck, Jaime Cecilio Hallak, Eduardo Nakano, Helio Elki. Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. Psychiatry research. vol 188. issue 3. 2011-09-27. PMID:21596442. |
a retrospective observational study was conducted designed to evaluate time to rehospitalization of patients with schizophrenia discharged on a regimen of oral fga, depot fga, risperidone, olanzapine and amisulpride, other sga, or clozapine, during a three-year follow-up period. |
2011-09-27 |
2023-08-12 |
Not clear |
| Anna Dietrich-Muszalska, Beata Olas, Bogdan Kontek, Jolanta Rabe-Jabłońsk. Beta-glucan from Saccharomyces cerevisiae reduces plasma lipid peroxidation induced by haloperidol. International journal of biological macromolecules. vol 49. issue 1. 2011-09-16. PMID:21421004. |
since oxidative stress observed in schizophrenia may be caused partially by the treatment of patients with various antipsychotics, the aim of the study was to establish the effects of beta-d-glucan, polysaccharide derived from the yeast cell walls of species such as saccharomyces cerevisiae, and the antipsychotics (the first generation antipsychotic (fga) - haloperidol and the second generation antipsychotic (sga) - amisulpride) action on plasma lipid peroxidation in vitro. |
2011-09-16 |
2023-08-12 |
human |
| Armida Mucci, Giuseppe Piegari, Silvana Galderis. Cognitive-enhancing effects of aripiprazole: a case report. Clinical practice and epidemiology in mental health : CP & EMH. vol 4. 2011-07-14. PMID:18959801. |
before schizophrenia onset his cognitive functioning was poor and he could not attend regular courses to reach his high school degree; he started but was not able to attend the university courses for several years.after schizophrenia onset, he was treated, in sequence, with olanzapine, amisulpride and aripiprazole. |
2011-07-14 |
2023-08-12 |
Not clear |
| Ashish Aggarwal, Manish Jain, Ashish Khandelwal, R C Jiloh. Amisulpride induced mania. Indian journal of pharmacology. vol 42. issue 2. 2011-07-14. PMID:20711379. |
amisulpride is an atypical antipsychotic used for the management of schizophrenia and other conditions like dysthymia. |
2011-07-14 |
2023-08-12 |
Not clear |
| Ashish Aggarwal, Manish Jain, Ashish Khandelwal, R C Jiloh. Amisulpride induced mania. Indian journal of pharmacology. vol 42. issue 2. 2011-07-14. PMID:20711379. |
here, we report a patient of schizophrenia who developed a manic episode while on amisulpride. |
2011-07-14 |
2023-08-12 |
Not clear |
| Mario F Juruena, Eduardo Pondé de Sena, Irismar Reis de Oliveir. Safety and tolerability of antipsychotics: focus on amisulpride. Drug, healthcare and patient safety. vol 2. 2011-07-14. PMID:21701632. |
as would be predicted from the pharmacologic profile of a pure d(2)/d(3) receptor blocker, amisulpride is an atypical antipsychotic agent, effective for positive and negative symptoms, which can bring about additional improvement in the social functioning and quality of life of patients with schizophrenia. |
2011-07-14 |
2023-08-12 |
Not clear |
| Mario F Juruena, Eduardo Pondé de Sena, Irismar Reis de Oliveir. Safety and tolerability of antipsychotics: focus on amisulpride. Drug, healthcare and patient safety. vol 2. 2011-07-14. PMID:21701632. |
amisulpride is effective in acute schizophrenia as determined by clinical global impression scores. |
2011-07-14 |
2023-08-12 |
Not clear |
| Ann M Mortime. Update on the management of symptoms in schizophrenia: focus on amisulpride. Neuropsychiatric disease and treatment. vol 5. 2011-04-26. PMID:19557121. |
update on the management of symptoms in schizophrenia: focus on amisulpride. |
2011-04-26 |
2023-08-12 |
Not clear |